Roy Jakobs, Chief Executive Officer of Royal Philips, continues to reinforce the company’s strategic focus on image-guided therapy with the announced agreement to acquire SpectraWAVE, an innovative U.S.-based company specializing in advanced vascular imaging technologies.
Under Jakobs’ leadership, Philips has been accelerating investments in high-impact clinical areas where technology can significantly improve patient outcomes. The acquisition of SpectraWAVE aligns with this strategy by expanding Philips’ capabilities in intravascular imaging, angiography-based physiological assessment, and the application of artificial intelligence in medical imaging. SpectraWAVE develops advanced solutions for the diagnosis and treatment of coronary artery disease, the most common form of heart disease worldwide, affecting more than 300 million people. Its technologies enable physicians to better visualize coronary arteries and make more precise, data-driven decisions during interventional procedures.
Founded in 2017 and headquartered in Bedford, Massachusetts, SpectraWAVE employs more than 70 professionals and has built a strong reputation for innovation in high-definition intravascular imaging and AI-powered physiological assessment tools. Roy Jakobs highlighted that Philips’ global leadership in image-guided therapy is rooted in close clinical collaboration combined with deep expertise in hardware, software, and artificial intelligence. He emphasized that Philips’ integrated portfolio brings together systems and interventional devices on a single platform, Azurion, used by clinicians around the world. By integrating SpectraWAVE’s technologies into this ecosystem, the manager aims to further enhance Philips’ offering in coronary interventions. The move reflects a broader commitment to expanding access to advanced, AI-enabled care while improving procedural efficiency and patient outcomes.
Since becoming CEO, Roy Jakobs has consistently emphasized innovation with purpose, leveraging cutting-edge technology to address some of the world’s most pressing health challenges. The SpectraWAVE agreement marks another step in Philips’ long-term vision to deliver better care to more people through smarter, more connected healthcare solutions.